Strategy

Small molecules or biologics: that's the question

Read more

Are botanical drugs a new model for pharma?

Read more

A start-up genomics company explains why open-source software is important

Read more

Time to engage with stem-cell therapy

Read more

Interview: 4-Antibody AG - How do you structure a biotech for divestment?

Read more

A Big Pharma deal that shares risk and reward

Read more

Focus on ophthalmology: new treatment modality

Read more

Due diligence is more than a numbers game

Read more

Kymab unlocks the power of the mouse

Read more

The role of technology providers in biotech

Read more